Senior/Research Associate, Functional Genomics at NewLimit

South San Francisco, California, United States

Apply Now

Not SpecifiedCompensation

Mid-level (3 to 4 years), Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

BiotechnologyIndustries

Requirements

Bachelor’s degree in cell biology, molecular biology, or a related natural science or industry experience
2+ years of work experience in a cell or molecular biology laboratory (academic or industry)
Experience with molecular cloning, nucleic acid analysis (RT-qPCR, gel electrophoresis), and related molecular biology methods
Experience with mammalian cell culture

Responsibilities

Collaborate with our Single Cell Technology team to implement large-scale, single cell perturbation experiments with custom chemistries
Build recombinant DNA vectors by synthesis and cloning to enable large-scale single cell perturbation experiments
Prepare, titer, and apply viral vectors (lentiviral, AAV) to transduce mammalian cell lines and primary cells
Contribute to scaling and improving pooled single cell perturbation screens

Skills

Key technologies and capabilities for this role

molecular cloningRT-qPCRgel electrophoresismammalian cell culturelentiviral vectorsAAVFACSflow cytometryPythonUnixnext-generation sequencingsingle cell genomicspooled perturbation screening

Questions & Answers

Common questions about this position

What is the salary range for the Senior/Research Associate position?

The salary range is $60,000 to $98,000, depending on qualifications, skills, competencies, and experience.

What benefits does NewLimit offer?

Benefits include health, dental, and vision insurance, 401(k) with company match, paid parental leave, 20 days of PTO per year plus holidays, and meals and snacks on-site.

Is this position remote or on-site?

This information is not specified in the job description.

What skills are required for this role?

Required skills include a Bachelor’s degree in cell biology, molecular biology, or related field, 2+ years of lab experience, molecular cloning, nucleic acid analysis (RT-qPCR, gel electrophoresis), and mammalian cell culture.

What experience makes a candidate stand out for this position?

Nice-to-have experience includes next-generation sequencing assays, functional genomics, FACS or flow cytometry, computational skills (Python, Unix), single cell genomics methods, and epigenetic reprogramming or targeted epigenetic editing.

NewLimit

Medicines for healthspan extension via epigenetics

About NewLimit

NewLimit develops medicines aimed at extending human healthspan by reprogramming aging cells' epigenomes. This involves changing the chemical modifications on DNA and histone proteins to restore youthful functions in old cells, focusing initially on rejuvenating the immune system and liver. The company uses advanced technologies like single-cell genomics and machine learning to identify aging markers and create interventions that reverse these changes. Unlike competitors, NewLimit's approach is centered on epigenetic reprogramming, targeting age-related diseases with the goal of creating a new class of medicines that enhance health during aging. The company serves the healthcare market, working with pharmaceutical companies and healthcare providers, and aims to transform aging by developing effective treatments.

South San Francisco, CaliforniaHeadquarters

2022Year Founded

$38.9MTotal Funding

SERIES_ACompany Stage

Biotechnology, HealthcareIndustries

11-50Employees

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Parental Leave

Unlimited Paid Time Off

Risks

Rapid biotech advancements could render NewLimit's technologies obsolete without continuous innovation.

Ethical concerns and regulatory scrutiny may delay product approvals.

Competition from similar biotech firms could impact NewLimit's market share.

Differentiation

NewLimit focuses on epigenetic reprogramming to extend human healthspan.

The company uses single-cell genomics and machine learning for drug discovery.

NewLimit targets age-related diseases with unmet needs, like immune system and liver rejuvenation.

Upsides

Increased interest in epigenetic reprogramming boosts NewLimit's market potential.

Machine learning aids in identifying novel drug candidates for age-related diseases.

FDA's favorable stance on aging therapies accelerates NewLimit's market entry.

Land your dream remote job 3x faster with AI

Try Jobo Free